

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Smooore International Holdings Limited

思摩爾國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 06969)

FINANCIAL UPDATE FOR THE PERIOD ENDED 31 MARCH 2026

This announcement is made by the board of directors (the “**Board**”) of Smooore International Holdings Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and based on the unaudited consolidated management accounts of the Company and its subsidiaries (collectively, the “**Group**”) for the three months ended 31 March 2026 (the “**Period**”).

EVE Energy Co., Limited (“**EVE Energy**”), one of the controlling shareholders of the Company listed on the Shenzhen Stock Exchange, is required to issue quarterly financial reports pursuant to the Rules Governing the Listing of Shares on the ChiNext Market of Shenzhen Stock Exchange. As the quarterly financial reports of EVE Energy will include certain financial information which could be considered to be indicative of the Group’s total comprehensive income for the same period, the Company has decided that, in addition to the regulatory announcements of interim and annual financial results, the Company will also announce the Group’s total comprehensive income for first and third quarters of a financial year.

Furthermore, EVE Energy is currently applying for a global offering on the Stock Exchange of Hong Kong Limited, and its prospectus will include certain financial information of the Group as of 31 March 2026. To ensure that all shareholders of the Company receive consistent information, in addition to the Group’s total comprehensive income for the first quarter of 2026, the Company has decided to disclose certain financial data of the Group as of 31 March 2026 herewith.

	Three Months Ended		
	31 March		
	2026	2025	Change
	<i>RMB million</i>	<i>RMB million</i>	%
	Unaudited	Unaudited	
Revenue	3,856.0	2,721.5	41.7%
Corporate client oriented business	3,267.4	2,198.9	48.6%
—Electronic vaping products and related technical services, and special purpose atomization products	2,524.1	2,071.6	21.8%
—Heat-not-burn products and technical services	664.0	46.6	1324.9%
—Inhalation therapy technical services	79.3	80.7	-1.7%
Self-branded business	588.6	522.6	12.6%
—Electronic vaping products	581.0	508.5	14.3%
—Beauty atomization products	7.6	14.1	-46.1%
Profit before tax	363.5	254.6	42.8%
Profit for the Period	262.5	192.2	36.6%
Total comprehensive income	127.9	207.8	-38.5%
Adjusted profit for the Period ¹	347.0	313.6	10.7%
Adjusted profit for the Period, excluding Inhalation therapy business ²	467.0	371.5	25.7%

As of
31 March 2026
RMB million
Unaudited

Current assets	16,744.1
Non-current assets	10,940.8
Current liabilities	5,146.0
Non-current liabilities	442.0
Net assets (Excluding Goodwill)	22,096.9
Equity attributable to shareholders of the Company	22,061.0
Non-controlling interests	35.9

1 Adjusted profit for the Period = Profit for the Period + Share-based payment expenses. The share-based payment expenses amounted to approximately RMB84.5 million during the Period (the same period in 2025: approximately RMB121.4 million).

2 Adjusted profit for the Period, excluding Inhalation therapy business = Adjusted profit for the Period – Profit/loss for the Period of Inhalation therapy business. Loss for the Period of Inhalation therapy business amounted to approximately RMB120.0 million (the same period in 2025: approximately RMB57.9 million).

During the Period, the Group recorded revenue of approximately RMB3,856.0 million, representing a robust year-on-year increase of 41.7%. This robust performance was driven by growth in both the corporate client oriented business (“**To B**”) and self-branded business.

Revenue from the ToB business was approximately RMB3,267.4 million during the Period, representing a strong year-on-year growth of 48.6%. The growth was mainly attributable to the continued growth in electronic vaping business and heat-not-burn (“**HNB**”) business.

Revenue from electronic vaping products and related technical services and special purpose atomization products were approximately RMB2,524.1 million during the Period, representing a solid year-on-year increase of 21.8%. Leveraging strong policy foresight, market insights and manufacturing excellence, the Group further supported its vaping ODM customers in achieving growth across major markets.

During the Period, revenue from HNB products and technical services was approximately RMB664.0 million, representing a year-on-year increase of 1324.9%. The significant increase of revenue was mainly due to the Group’s support of its strategic customer in rolling out premium HNB products in the second half of 2025.

The Group’s inhalation therapy business recorded revenue of approximately RMB79.3 million during the Period, representing a slight year-on-year decrease of 1.7%. Revenue from inhalation therapy business was mainly from technical services provided to corporate customers. During the Period, the inhalation therapy business progressed as scheduled.

Revenue from the Group’s self-branded business was approximately RMB588.6 million during the Period, representing a year-on-year growth of 12.6%. The increase was driven by the Group’s self-branded electronic vaping business, which continued to gain market share in emerging markets during the Period.

During the Period, profit for the Period was approximately RMB262.5 million, representing a year-on-year growth of 36.6%, primarily driven by (i) an increase in revenue and gross profit, (ii) a decrease in distribution and selling expenses. Excluding share-based payment expenses, adjusted profit for the Period amounted to approximately RMB347.0 million, representing a year-on-year increase of 10.7%.

During the Period, the Group continued to invest in Transpire Bio Inc. (“**Transpire**”). Its inhalation therapy business focuses on the enhancement of Transpire’s in-house technology platforms and pipeline products to support its long-term business development. Excluding the losses from this business, adjusted profit for the Period was approximately RMB467.0 million, representing a year-on-year increase of 25.7%.

The information contained in this announcement is only based on the preliminary review on the unaudited consolidated management accounts of the Group, which have not been reviewed by the independent auditors. The aforesaid information may not be indicative of the financial performance of the Group for its full financial year. Shareholders and potential investors are advised not to place reliance on the aforesaid information and advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Smooore International Holdings Limited
Mr. Chen Zhiping
Chairman of the Board

Hong Kong, 9 April 2026

As at the date of this announcement, the Executive Directors are Mr. Chen Zhiping, Mr. Xiong Shaoming, Mr. Wang Guisheng and Ms. Wang Xin; the Non-executive Director is Ms. Jiang Min; and the Independent Non-executive Directors are Mr. Zhong Shan, Mr. Yim Siu Wing, Simon and Dr. Wang Gao.